Literature DB >> 17242855

Survey of pharmacists' attitudes towards interchangeable use of dry powder inhalers.

Angela E Williams1, Henry Chrystyn.   

Abstract

BACKGROUND: It is a common cost-containment practice in some countries to dispense a cheaper, generic version of a prescribed medication. This presents few problems for most medications. However, dry powder inhalers used in asthma and COPD vary markedly in design and method of operation, so generic substitution may not be acceptable to patients or healthcare professionals. Patients dispensed an unfamiliar device in which they have received no training, risk poor inhalation technique with the potential for inadequate dosing and loss of disease control.
OBJECTIVE: To assess the views of pharmacists towards interchangeable use of dry powder inhalers.
SETTING: Community pharmacists in Australia, Canada, France, Germany, and the UK.
METHOD: Following exploration of the key issues with international opinion leaders in respiratory management, a structured web questionnaire was developed for use in computer assisted web interviews. Fieldwork was carried out in March and April 2005. MAIN OUTCOME MEASURE: Responses to the web questionnaire were analysed by percentage of respondents or by mean or median score, as appropriate to the question.
RESULTS: A total of 254 pharmacists were included in the study. Just 6% of pharmacists considered that dry powder inhalers are interchangeable, with a high level of concern shown about interchangeable use (median score of 6 on a scale of 1, not at all concerned, to 7, extremely concerned). Patient confusion was the main concern, expressed by 77% of respondents. Pharmacists also envisaged substitution having an adverse impact on pharmacy stock levels (72%), patient device handling (70%), pharmacist workload (63%), patient compliance (56%) and outcomes for the patient (51%), with pharmacists in Germany having a particularly negative view and those in France generally the most positive. Despite the generally negative view of pharmacists about interchangeable use of dry powder inhalers, overall only 22% would contact the prescribing physician often/very often for approval of the substitution.
CONCLUSION: The study showed that only a small minority of pharmacists believe that dry powder inhalers can be used interchangeably, with the majority concerned about generic substitution of these products. Pharmacists in Germany were particularly negative about the interchangeable use of dry powder inhalers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242855     DOI: 10.1007/s11096-006-9079-6

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  17 in total

Review 1.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 2.  Do all dry powder inhalers show the same pharmaceutical performance?

Authors:  A Taylor; P Gustafsson
Journal:  Int J Clin Pract Suppl       Date:  2005-12

Review 3.  Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes.

Authors:  W P Adams; G Poochikian; A S Taylor; R M Patel; G P Burke; R L Williams
Journal:  J Aerosol Med       Date:  1994

Review 4.  Can patients use all dry powder inhalers equally well?

Authors:  P Gustafsson; A Taylor; P Zanen; H Chrystyn
Journal:  Int J Clin Pract Suppl       Date:  2005-12

Review 5.  Do patients show the same level of adherence with all dry powder inhalers?

Authors:  H Chrystyn
Journal:  Int J Clin Pract Suppl       Date:  2005-12

Review 6.  Do patients think that dry powder inhalers can be used interchangeably?

Authors:  R Booker
Journal:  Int J Clin Pract Suppl       Date:  2005-12

7.  Future options for aerosol delivery to children.

Authors:  H Bisgaard
Journal:  Allergy       Date:  1999       Impact factor: 13.146

8.  Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.

Authors:  E D Bateman; V Silins; M Bogolubov
Journal:  Respir Med       Date:  2001-02       Impact factor: 3.415

Review 9.  The costs of asthma.

Authors:  P J Barnes; B Jonsson; J B Klim
Journal:  Eur Respir J       Date:  1996-04       Impact factor: 16.671

10.  Risk factors and costs associated with an asthma attack.

Authors:  G Hoskins; C McCowan; R G Neville; G E Thomas; B Smith; S Silverman
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

View more
  7 in total

1.  Development and validation of a tool to assess knowledge and attitudes towards generic medicines among students in Greece: The ATtitude TOwards GENerics (ATTOGEN) questionnaire.

Authors:  Philip J Domeyer; Vassilis Aletras; Fotios Anagnostopoulos; Vasiliki Katsari; Dimitris Niakas
Journal:  PLoS One       Date:  2017-11-29       Impact factor: 3.240

Review 2.  The Nurse Practitioners' Perspective on Inhaler Education in Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  Jane Scullion
Journal:  Can Respir J       Date:  2018-08-05       Impact factor: 2.409

3.  General Practitioner Use of Generically Substitutable Inhaler Devices and the Impact of Training on Device Mastery and Maintenance of Correct Inhaler Technique.

Authors:  Biljana Cvetkovski; Charlotte Hespe; Rachel Tan; Vicky Kritikos; Elizabeth Azzi; Sinthia Bosnic-Anticevich
Journal:  Pulm Ther       Date:  2020-10-10

4.  Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control.

Authors:  Mike Thomas; David Price; Henry Chrystyn; Andrew Lloyd; Angela E Williams; Julie von Ziegenweidt
Journal:  BMC Pulm Med       Date:  2009-01-02       Impact factor: 3.317

Review 5.  What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs.

Authors:  Suzanne S Dunne; Colum P Dunne
Journal:  BMC Med       Date:  2015-07-29       Impact factor: 8.775

Review 6.  Switching treatments in COPD: implications for costs and treatment adherence.

Authors:  Fulvio Braido; Federico Lavorini; Francesco Blasi; Ilaria Baiardini; Giorgio Walter Canonica
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-12-03

7.  Generic medicine substitution: a cross-sectional survey of the perception of pharmacists in North-Central, Nigeria.

Authors:  Asa Auta; Echuku Tercee Bala; David Shalkur
Journal:  Med Princ Pract       Date:  2013-11-05       Impact factor: 1.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.